Comparing Physician and AI Decisions on Trigger Day Timing During GnRH Antagonist Ovarian Stimulation for IVF

What this Trial Is About

This research focuses on patients undergoing ovarian stimulation cycles using the GnRH antagonist protocol for either oocyte cryopreservation or fertilization via intracytoplasmic sperm injection ICSI. It aims to compare the number of mature eggs produced when the timing of the trigger day is decided by physicians versus an artificial intelligence-based algorithm. The study evaluates how these two approaches affect in-vitro fertilization IVF outcomes. Participants are randomly assigned to one of two groups one where the trigger day timing is determined by the treating physician, and another where an artificial intelligence-based algorithm makes this decision. This intervention occurs during the ovarian stimulation cycle involving GnRH antagonist protocols, with mature oocyte yield as the primary measure. Throughout the study, researchers will monitor the number of mature eggs collected over a two-year period. Participants will undergo standard ovarian stimulation and oocyte retrieval procedures, with outcomes measured by mature and total oocyte yield. The study includes follow-up to assess these outcomes and ensure patient safety during the trial period, which spans from May 2025 to May 2028.

Ovarian Stimulation Outcomes During a GnRH Antagonist Protocol for In-vitro Fertilization When Comparing Trigger Day Decision by Physicians Versus an Artificial Intelligence-based Algorithm.